KLRK1 and plasma cell myeloma: A comparative analysis using NK-92 cells further supported these findings, showing that NKG2D CAR-NK cells achieved comparable or superior anti-myeloma activity relative to BCMA-CAR constructs, reflecting their broader recognition of stress ligands expressed on tumor cells [126].